Serum heme oxygenase-1 as a prognostic biomarker in patients with acute exacerbation of interstitial lung disease

• Published in: Scientific reports Vol. 13; no. 1; p. 22639
• Main Authors: Tagami, Yoichi, Hara, Yu, Murohashi, Kota, Nagasawa, Ryo, Fujii, Hiroaki, Izawa, Ami, Yabe, Aya, Saigusa, Yusuke, Kobayashi, Miyu, Shiida, Masafumi, Hirata, Momo, Otsu, Yukiko, Watanabe, Keisuke, Horita, Nobuyuki, Kobayashi, Nobuaki, Kaneko, Takeshi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 19.12.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308; 692/308/53; 692/308/53/2422; Biomarkers; Comorbidity; Diagnosis; Disease Progression; Effectiveness; Fibrosis; Heme oxygenase (decyclizing); Heme Oxygenase-1; Humanities and Social Sciences; Humans; Idiopathic Pulmonary Fibrosis; Infant, Newborn; Lung diseases; Lung Diseases, Interstitial; Morbidity; Mortality; multidisciplinary; Prognosis; Retrospective Studies; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-49342-4

Serum heme oxygenase (HO)-1 level has been reported as a clinically reliable diagnostic biomarker for acute exacerbation of interstitial lung disease (ILD); however, its utility for predicting mortality among these patients is unclear. Serum HO-1 levels of patients newly diagnosed with acute exacerbation of ILD were measured at the time of initiating steroid pulse therapy. The relationship between serum HO-1 and various other serum biomarkers, change in HRCT findings, and disease prognosis at 12 weeks after diagnosis of acute exacerbation was evaluated in 51 patients, of whom 17 (33%) had idiopathic pulmonary fibrosis (IPF). Serum HO-1 was higher in patients with acute exacerbation of IPF than in patients with acute exacerbation of other ILDs. Serum HO-1 levels were higher in patients who died within these 12 weeks than in survivors. Among age, sex, comorbidities, IPF diagnosis, HRCT findings, and blood biomarkers, serum HO-1 was a primary predictor of 12-week mortality. In 41 patients who underwent repeat HRCT, serum HO-1 was higher in patients with honeycomb progression than in those without. Serum HO-1 measurement could be useful for evaluating disease mortality and morbidity of patients with acute exacerbation of ILDs.